Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of UnyveroTM Cartridge Plastics Parts
Holzgerlingen (Germany), December 4, 2012 -- Curetis AG today announced a strategic supply chain partnership with German family business Horst Scholz GmbH + Co. KG for the production of high-quality plastics parts for its Unyvero™ Cartridge.
Under the agreement, Curetis will invest more than € 2 million in multi-cavity tools for all Unyvero™ Cartridge plastics parts. Curetis has already ordered several multi-cavity tools from Scholz. The first tools will be delivered in early 2013.
Scholz has been chosen by Curetis due to its unrivalled experience and expertise in medical device-grade injection molding, its state-of-the-art facilities and equipment as well as its cleanroom manufacturing infrastructure.
Scholz has a long track record and outstanding commitment to total quality management, e.g. regarding the use of CT scanners for quality control of parts. Curetis expects a smooth transition from its previous R&D phase supplier to the serial production and scale-up run by its new partner Scholz.
“With the selection of Scholz, we have significantly de-risked our scale-up efforts,” said Oliver Schacht, CEO of Curetis. “We expect to considerably lower the cost of goods for our Unyvero cartridges in the coming years due to substantially reduced purchase prices for plastics parts while retaining the highest possible quality standards. Moreover, both parties have aligned their commercial interests over the long term. With its German supply chain partners Zollner for instruments and now Scholz for cartridge parts, Curetis has reached the next phase of commercialization and industrial growth. Cartridge manufacturing will continue unchanged at our Bodelshausen facility.”
“We are extremely pleased that Curetis has chosen us as its partner for the industrialization and scale-up in manufacturing top quality injection-molded plastics parts for their Unyvero cartridges,” stated Gertrud Ebert, CEO of Scholz. “We have already begun the transfer process and will support Curetis with every step along the way, in the transition phase as well as in the anticipated growth over the years to come.”
About the Unyvero™ System
The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.
The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.
Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.
The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second Unyvero™ application for implant & tissue infections is already in product development. Cartridges for additional indications, such as blood stream infections and tuberculosis, are in preparation.
About Horst Scholz GmbH & Co. KG
Founded in 1974, Scholz provides its customers with complete solutions in the areas of precision plastic parts, development of plastic gear drives and microtechnology, including Micro Metal Injection Moulding (MMIM). Services range from design through development and manufacturing of the tools in Scholz´s own toolmaking department and the subsequent injection molding up to module production. A certified Management System according to ISO/TS 16949:2002; DIN EN ISO 9001:2000; DIN EN ISO 14001; and DIN EN ISO 13485 guarantees a self-optimizing control circuit for high-end products in the micro-, gearing and medicine technology markets as well as the automobile industry.
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
About Curetis AG
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical, Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements.
Oliver Schacht, CEO
71088 Holzgerlingen, Germany
Tel. +49 (0) 7031 49195-10
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of UnyveroTM Cartridge Plastics Parts here
News-ID: 245329 • Views: 1586
More Releases from Curetis AG
Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyv …
− Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Robin Patel, M.D., Professor of Medicine and Microbiology at the Mayo Clinic in Rochester, Minn., has been named Lead Principal Investigator of the company’s Unyvero™ LRT Application FDA trial. The lower respiratory tract (LRT) application is
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
- Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples - Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more
Curetis Completes Enrollment for its EU Trial As Planned
- Prospective multi-center trial enrolls 800 patient samples in 7 months - Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal. The trial will compare the
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
- Partners to start registration process and market launch in Russia - Holzgerlingen, Germany, September 27, 2012 -- Curetis AG today announced that it has signed up BioLine LLC as an exclusive distribution partner for Russia, Ukraine, Kazakhstan and Belorus. BioLine is a major player in these markets and distributor for global companies such as Becton Dickinson, Leica Microsystems and many others. BioLine is preparing the registration of the Unyvero™ Solution and
More Releases for Scholz
The New Power of the Pharmaceutical Industry: Covid-19 Vaccines and the Social R …
"Pricing and distribution of Covid-19 vaccines can intensify global and social inequality," argues business ethicist based in Austria in a recent publication. Vienna, November 5th, 2020 – The initial scarcity of effective vaccines against Covid-19 entails an enormous social responsibility to the producing pharmaceutical companies. If the pricing and distribution of this scarce health resource were to be based exclusively on traditional market principles, rich countries and members of the upper
La Ola ist the new Trance-Track of Jane van Daan
La Ola is the third single by Jane van Daan. It transports exuberant party mood. In times of corona, the party has to be started at home. Nevertheless: La Ola is the right party hit to master the isolation time and to lift the mood. When the lock down ist over and the clubs re-open, La Ola will bring every dancefloor to top atmosphere. Although the production of this track was
Drive high CAGR by Global Chromium Oxide Green Market Along with Top Key Players …
Chromium Oxide Green Market Industrial Forecast on Chromium Oxide Green Market: A new research report titled, ‘Global Chromium Oxide Green Market Size, Status and Forecast 2019-2023’ have been added by Reports Monitor to its huge collection of research report with grow significant CAGR during Forecast .The research report analyzes the Global market in terms of its size, status, forecast, trends, competitive scenario, and potential growth opportunities. The Chromium Oxide Green Market report categorizes the
Shortfilm-Soundtrack "Obsedo" (Trance) now available
It started as a filmscore for the shortmovie Obsedo (obsession in english) from the moviemaker Mareike Gabrisch composed by the Filmcomposer Florian C. Scholz. This film needed an trance-like track for some reasons. The mainplot takes place in a disco/club. We decided to do an EP with Jane Van Daan and this track. To add some value we did not only the short and club version, we added four more remixes.
Chromium Oxide Green Market Report for Period 2018 till 2022 Jirong Chemical, El …
Global Chromium Oxide Green market report emphasizes on detailed analysis of companies and manufacturers like Lanxess, Harold Scholz, Hebei Chromate Chemical, Luoyang Zhengjie, Jirong Chemical, Elementis, Hunter Chemical, Sun Chemical, Hunstman (Venator) and Others. This report studies the Chromium Oxide Green market, Chromium oxide green, also known as chromium sesquioxide or chromia, is one of four oxides of chromium, chemical formula Cr2O3. It is commonly called chrome green when used
New specialist book on IT systems for public transport companies
Public transport companies work with advanced information technology in order to plan, optimise and manage their fleets. The buses themselves have meanwhile also become high-tech vehicles. The complex IT systems that are involved are described in the new book ‘IT-Systeme für Verkehrsunternehmen: Informationstechnik im öffentlichen Personenverkehr’ (IT systems for transport companies – Information technology in public transport). Dr Gero Scholz, expert in logistics and computer sciences, describes the demands faced